Drug name - Wegovy

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(9 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof Aug, 2038

(15 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.25MG/0.5ML (0.25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
0.5MG/0.5ML (0.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1MG/0.5ML (1MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1.7MG/0.75ML (1.7MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription
2.4MG/0.75ML (2.4MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.